2025-06-11-花旗集团-医科达公司（EKTAB）_医科达公司（公开上市）（EKTAb.ST）_CMD要点_战略转向但每股收益风险犹存；执行是关键；卖出_11页_255kb
报告摘要
- Recommendation: Sell
- Company Overview: Elekta AB (publ) is a Swedish firm specializing in radiation therapy and radiosurgery equipment for cancer and brain disorders treatment.
- Key Analysis: The company pivots to pricing discipline to improve margins, but this risks further share loss to Varian, potentially hindering revenue growth. Key risks include FX headwinds (~100bps), R&D costs (~100bps), and tariffs (~50bps) lowering projected margin expansion to ~14.2% in 2027/2028E. Near-term support comes from product rollouts like Elekta Evo, but China and US sales momentum remains cautious.
- Catalysts: Successful Elekta Evo launch, US reimbursement changes (e.g., hypofractionation legislation), and Elekta’s new pricing strategies could drive top-line acceleration.
- Financials: Projected net sales and net income decline (e.g., 2024A-2028E show shrinking EPS and revenue), with a target price of SKr39 (negative 19.3% expected share return) vs. current price, valuing at ~14x PE.
- Risks: Execution failures, market competition, China sales weakness, ongoing R&D spending, and geopolitical factors pose major threats to growth and profitability.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
